Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease

Archives of Neurology

Volumn 64, Issue 4, 2007, Pages 576-580

  Hancock, Dana B ^a   Martin, Eden R ^a   Stajich, Jeffrey M ^a   Jewett, Rita ^a,b   Stacy, Mark A ^a   Scott, Burton L ^a   Vance, Jeffery M ^a   Scott, William K ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; COFFEE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SELF REPORT; SMOKING HABIT; TEA;

EID: 34247140154     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.4.576     Document Type: Article

References (16)

1. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002;52:276-284.
2. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann Neurol. 2005;58:963-967.
3. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059-1064.
4. Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology. 2005; 64:442-447.
5. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
6. Bass MP, Martin ER, Hauser ER. Pedigree generation for analysis of genetic linkage and association. Pac Symp Biocomput. 2004;9:93-103.
7. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology. 2002;58:581-588.
8. Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology. 2006;66:1097-1099.
9. Ton TG, Heckbert SR, Longstreth WT, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord. 2006;21:964-969.
10. Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology. 2006;67:494-496.
11. Louis ED, Luchsinger JA, Tang MX, Mayeux R. Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology. 2003;61: 24-28.
12. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-319.
13. Pogun S, Demirgoren S, Taskiran D, et al. Nicotine modulates nitric oxide in rat brain. Eur Neuropsychopharmacol. 2000;10:463-472.
14. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem. 2001;76:1895-1904.
15. Mazzio EA, Kolta MG, Reams R, Soliman KFA. Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. Neurotoxicology. 2005;26:49-62.
16. Hancock DB, Martin ER, Fujiwara K, et al. NOS2A and the modulating effect of cigarette smoking in Parkinson's disease. Ann Neurol. 2006;60:366-373.